Displaying 1 - 12 items out of 21 results
Press release
… 2021, 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT) --Pre-treatment circulating tumor (ct)DNA levels more accurately predicted long-term survival than …
Press release
… PD-L1 inhibition overcomes T-cell suppression at the tumor; and chemotherapy causes tumor cell death and antigen … molecularly characterized via sequencing of tumor tissue DNA and/or circulating tumor DNA samples. Progression free survival and …
Press release
… services to cancer research. Her research interests span tumor biology, biomarker discovery, preclinical … Biomarker Research program, she became fascinated with circulating tumor cells (CTCs) for use as a liquid biopsy. … proud that some of the earliest work on circulating tumor DNA (ctDNA) done with AstraZeneca and Professor Andrew …
Press release
… complex malignancy. Liquid biopsy, and especially plasma ctDNA, can be used in many clinical settings where tissue is … that IASLC is in the forefront in this arena.” Although tumor tissue is historically the gold standard biospecimen … biopsy approach includes a variety of methodologies for circulating analytes. From a clinical point of view, plasma …
ILCN article
The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology
… Assessment of tumor material by the pathology laboratory has become a … who must maintain in-depth knowledge of rapidly changing tumor classification and staging systems as well as of … The detection of targetable genomic alterations by DNA and RNA sequencing has become a mainstay for prediction …
Press release
… a powerful tool that can determine the patient’s molecular tumor profile in order to determine the best therapeutic … applied as an alternative to tissue testing in cases where tumor testing is not possible or tissue is not adequate,” … rebiopsies. In this context, the isolation of tumor-derived DNA, RNA and cells from the peripheral circulation (a …
Spotlight
… of lung cancers harboring mutations in genes involved in DNA damage repair (DDR) derive improved clinical outcomes … of lung cancers harboring mutations in genes involved in DNA damage repair (DDR) derive improved clinical outcomes … in DDR genes are increasingly being identified in other tumor types, our findings could extend to other cancers in …
Press release
… Barcelona— Tumor mutational burden was not significantly associated … Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new data … by whole-exome sequencing of tumor and matched normal DNA. The clinical utility of TMB on outcomes was assessed …
Press release
… specific cancer’s growth and progression. Patients whose tumors harbor certain, specific molecular alterations may be … EGFR T790M in relapse may be done by biopsy or cell-free circulating DNA. However cell-free DNA is not appropriate for initial …
ILCN article
Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt
… strategies and methods used to determine the presence of tumors in the body by molecular examination of residual tumor DNA in the blood. MRD is not only a potential indicator …
Press release
… predictive biomarkers, which may enable better targeting of tumor characteristics. Its aims to accelerate development of … and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor …
Press release
… reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based … and pemetrexed or carboplatin and pemetrexed alone. Tumor mutational burden was determined by whole exome sequencing of tumor and matched normal DNA. Langer and the KEYNOTE 021 researchers were able to …